Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report from the University of Alabama, Birmingham describes a rare paradoxical reaction of increased agitation and hyperactivity in a patient with schizoaffective disorder treated with divalproex sodium.

This study suggests that among GLP-1 agonists, liraglutide and exenatide are linked to the highest rates of gastrointestinal issues, including potentially pancreatitis-related enzyme changes noted in animal models.

TAK-279 effectively reduces psoriasis symptoms and is safe.

This review examines the adverse skin reactions associated with antipsychotic medications and reports no new clinical findings, but suggests discussing management strategies to improve patient compliance.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

This study found that co-administering glucocorticoids with 5α-reductase inhibitors exacerbated the adverse metabolic effects of glucocorticoids in healthy men.

This abstract reviews the management of polycystic ovary syndrome and highlights the potential benefits of lifestyle changes over metformin in reducing type 2 diabetes risk, yet reports no new clinical outcomes.

This study reports that a 15-year-old with trichotillomania showed improvement with aripiprazole treatment, though no consensus on treatment exists in the literature.

This case report describes a patient who experienced rapid hair depigmentation after starting pazopanib for metastatic renal cell carcinoma, which may suggest therapy success despite being distressing.

In this study, researchers found that metformin improved glycaemic control and other metabolic parameters in non-diabetic patients on glucocorticoid treatment, also reducing pneumonia risk and hospital admissions, suggesting a potential advantage for routine use in this population.

This article describes how a new blood glucose management service at the NIH Clinical Center improved safety and patient outcomes for hospitalized patients with diabetes.

A medicine company has recalled a drug because it contained an unlisted blood pressure medication.

This article highlights the importance of recognizing, preventing, and reporting adverse drug reactions to the FDA's MedWatch program, but does not present new research findings.

This study found that patients using GLP-1 receptor agonists, specifically liraglutide, dulaglutide, and semaglutide, had a higher likelihood of being diagnosed with androgenetic alopecia, while those on exenatide showed increased odds for both androgenetic alopecia and telogen effluvium.

This narrative review discusses the mixed and evolving evidence regarding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their influence on erectile dysfunction in men with type 2 diabetes and obesity, highlighting potential benefits and concerns yet to be clarified.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

This study found that among users of glucagon-like peptide-1 receptor agonists, semaglutide and tirzepatide were associated with higher incidences of hair loss, particularly androgenetic alopecia and telogen effluvium, with rapid weight loss identified as a potential contributor to telogen effluvium.

This article describes a case of hypertrichosis potentially induced by using efalizumab but provides no new clinical study results.

This review article discusses the aesthetic impacts of GLP-1 medications like Ozempic (semaglutide), including "Ozempic Face," skin sagging, and loss of lean mass, and explores potential recovery methods such as biostimulators, HIFU, endolaser, and PRP.

This study provides a narrative review suggesting GLP-1 receptor agonists could optimize metabolic health before conception in women with PCOS, but not necessarily improve fertility outcomes, emphasizing individualized use and the need for further research to confirm their reproductive benefits and safety.

In this study, patients with epilepsy who switched from immediate-release to extended-release divalproex sodium did not experience significant changes in seizure frequency, but most preferred the new formulation due to a subjective decrease in tremor during daily activities.

In this case study, the researchers reported that treating a woman with type B insulin resistance using rituximab, dexamethasone, and cyclophosphamide greatly reduced her insulin needs, but her hyperandrogenic state persisted, suggesting ovarian hyperthecosis.

This study presents four cases of delusions of parasitosis and introduces escitalopram as a potential therapy, highlighting its fewer side effects compared to the commonly used pimozide.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

This review discusses the lack of long-term clinical studies on metformin's cardiovascular benefits in women with polycystic ovary syndrome, highlighting lifestyle changes as a crucial management strategy for reducing associated risks.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.